Catalog No.: PC-20041Not For Human Use, Lab Use Only.
BI 730357 (Bevurogant, BI-730357) is a potent selective RORγt antagonist with IC50 of 150 nM in reporter gene assays (RGA), inhibits the secretion of IL-17A of PBMCs with IC50 of 24 nM.
BI 730357 (Bevurogant, BI-730357) is a potent selective RORγt antagonist with IC50 of 150 nM in reporter gene assays (RGA), inhibits the secretion of IL-17A of PBMCs with IC50 of 24 nM.
BI 730357 showed potent IL-17 inhibition in the human whole blood setting (IC50=140 nM), inhibited human RORγ-mediated IL-22 production (IC50=43 nM) in human PBMCs.
BI 730357 shows no off-target activity in the typical screening panels of receptors and kinases.
BI 730357 (0.3, 3, and 30 mg/kg, oral) demonstrated significant inhibition of IL-17A mRNA in in vivo murine IL-23 minicircle model, and inhibition of the disease-relevant biomarkers S100a8, S100a9, and β-defensin in the skin (ED50 < 0.3 mg/kg).
